Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics
The DOI matches its Crossref record, with a small difference in title or year; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of vesicant intravenous infusions during hospital attention is another common factor potentially affecting this group of population, which could specially be present in patients receiving IV chemotherapy.52”
From Defining risk factors associated with difficult peripheral venous Cannulation: A systematic review and meta-analysis (2020) · cites this paper as [52]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Blockade of PD-1, a receptor expressed by T cells, modulates immune responses, and organ inflammation has been noted preclinically with this class of agents due to pharmacologic activity (Topalian et al. 2012).”
Background2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37715 · Cited by 6,631
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 2×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundEndothelial cells in physiology and in the pathophysiology of vascular disorders.
Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., et al. (1998) · PubMed · doi:10.1182/blood.v91.10.3527 · Cited by 2,256
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Probably, the most publicized case of clinical vascular damage due to proinflammatory peptide therapies involved a clinical trial in patients administered the anti-CD28 product TGN1412, and which resulted in effects that were not predicted preclinically (Suntharalingam et al. 2006).”
BackgroundAngiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924 · cited 1×
“Smooth muscle cells (SMCs) regulate vascular tone and have receptors for endogenous vasoconstrictors such as angiotensin, endothelin, and epinephrine, and are also a target for NO and ion channel openers (Nguyen Dinh Cat and Touyz 2011; Galley and Webster 2004; Mehta and Griendling 2007).”
BackgroundRobbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,571
Swine as Models in Biomedical Research and Toxicology Testing
Swindle, M. M., Makin, A., Herron, A. J., Clubb, F. J., & Frazier, K. S. (2012) · Veterinary Pathology · doi:10.1177/0300985811402846 · Cited by 1,357 · cited 2×
“Necrosis or thrombosis may occur and laminar thickening of the adventitia has been described (Swindle et al. 2012).”
BackgroundSelf-citationEffects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355 · cited 1×
“Drug or protein aggregates within the dosing solution can further enhance the immune recognition of a substance as ‘‘foreign’’ even without the participation of ADA (Rosenberg 2006; Leach 2013).”
BackgroundJennette, J. C., & Falk, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711203372106 · Cited by 1,323
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261 · cited 1×
“…ANCA antibodies, which involve direct activation of cytokineprimed neutrophils and monocytes and results in their degranulation and subsequent damage to the adjacent endothelium (Falk et al. 1990; Gao and Zhao 2009; Jennette, Falk, and Wilkman 1995; Radic, Martinovic Kaliterna, and Radic 2012).”
BackgroundCytokines and endothelial cell biology
Pober, J. S., & Cotran, R. S. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.427 · Cited by 1,242
The Spectrum of Vasculitis: Clinical, Pathologic, Immunologic, and Therapeutic Considerations
FAUCI, A. S., HAYNES, B. F., & KATZ, P. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-5-660 · Cited by 1,196 · cited 1×
“…considered a useful discriminator, because PAN- and ANCA-associated vasculitis in man can exhibit clinically and pathologically indistinguishable necrotizing arteritis of medium and small arteries (Amano, Hozama, and Hamaskima 1979; Fauci, Haynes, and Katz 1978; Jennette, Falk, et al. 2013).”
BackgroundOverview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864 · cited 2×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundTopper, J. N., Cai, J., Falb, D., & Gimbrone, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10417 · Cited by 843 · cited 1×
“EC activation is considered critical to the mechanism of vascular injury with many agents, including small molecules, biotherapeutics, and antisense oligonucleotide therapeutics (Cines et al. 1998; Frazier 2014; Joseph 2000; Dai et al. 2004; Gimbrone, Nagel, and Topper 1997; Topper et al. 1996).”
BackgroundTHE ROLE OF ENDOTHELIAL CELLS IN INFLAMMATION
POBER, J. S., & COTRAN, R. S. (1990) · Transplantation · doi:10.1097/00007890-199010000-00001 · Cited by 799
Gill, M., Dias, S., Hattori, K., Rivera, M. L., Hicklin, D., Witte, L., Girardi, L., Yurt, R., Himel, H., & Rafii, S. (2001) · Circulation Research · doi:10.1161/01.res.88.2.167 · Cited by 798 · cited 1×
“The degree of vascular injury has been shown to correlate with increases in the number of CECs in circulation (Gill et al. 2001; Wu, Chen, and Hu 2007).”
BackgroundNovel Clinical Markers of Vascular Wall Inflammation
Blake, G. J., & Ridker, P. M. (2001) · Circulation Research · doi:10.1161/hh2101.099270 · Cited by 754
Galley, H. F., & Webster, N. R. (2004) · British Journal of Anaesthesia · doi:10.1093/bja/aeh163 · Cited by 697 · cited 1×
“Smooth muscle cells (SMCs) regulate vascular tone and have receptors for endogenous vasoconstrictors such as angiotensin, endothelin, and epinephrine, and are also a target for NO and ion channel openers (Nguyen Dinh Cat and Touyz 2011; Galley and Webster 2004; Mehta and Griendling 2007).”
BackgroundDai, G., Kaazempur-Mofrad, M. R., Natarajan, S., Zhang, Y., Vaughn, S., Blackman, B. R., Kamm, R. D., García-Cardeña, G., & Gimbrone, M. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406073101 · Cited by 664 · cited 1×
“EC activation is considered critical to the mechanism of vascular injury with many agents, including small molecules, biotherapeutics, and antisense oligonucleotide therapeutics (Cines et al. 1998; Frazier 2014; Joseph 2000; Dai et al. 2004; Gimbrone, Nagel, and Topper 1997; Topper et al. 1996).”
BackgroundThe Many Faces of Endothelial Microparticles
Dignat-George, F., & Boulanger, C. M. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.218123 · Cited by 635 · cited 2×
“EMP can serve as surrogate markers of endothelial function and elevated levels of EMP have been seen in patients with vascular diseases, and may correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-…”
BackgroundAggregates in monoclonal antibody manufacturing processes
Vázquez‐Rey, M., & Lang, D. A. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23155 · Cited by 479 · cited 2×
“Nonendogenous IgG aggregates, including those derived from mAb, can simulate immune complexes within the bloodstream, stimulate a local immune response, and result in local hypersensitivity reactions (Vazquez-Rey and Lang 2011).”
BackgroundComplement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478 · cited 2×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundCirculating endothelial cells: Biomarker of vascular disease
Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., Haubitz, M., Hebbel, R. P., Lip, G. Y. H., Mancuso, P., Sampol, J., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0578 · Cited by 390 · cited 3×
“…injury by a variety of means including those related to damage from cytokines, immune complexes, complement dysregulation, or T-cell activation (Blann et al. 2005; Constans and Conri 2006; Day, Hewins, and Savage 2003; Filer et al. 2003; Kollmeier et al. 1998; Langford 2003; Sibelius et al.…”
BackgroundEndothelial Cell Activation by Leukocyte Microparticles
Mesri, M., & Altieri, D. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4382 · Cited by 373 · cited 1×
“…correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-George and Boulanger 2011; Erdbruegger et al. 2008, Erdbruegger, Dhaygude, and Woywodt 2011; Mesri and Altieri 1998; 1999).”
BackgroundMesri, M., & Altieri, D. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23111 · Cited by 349 · cited 1×
“…correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-George and Boulanger 2011; Erdbruegger et al. 2008, Erdbruegger, Dhaygude, and Woywodt 2011; Mesri and Altieri 1998; 1999).”
BackgroundBiomechanical activation: an emerging paradigm in endothelial adhesion biology.
Gimbrone, M. A., Nagel, T., & Topper, J. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119346 · Cited by 347 · cited 1×
“EC activation is considered critical to the mechanism of vascular injury with many agents, including small molecules, biotherapeutics, and antisense oligonucleotide therapeutics (Cines et al. 1998; Frazier 2014; Joseph 2000; Dai et al. 2004; Gimbrone, Nagel, and Topper 1997; Topper et al. 1996).”
BackgroundDynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells
Rondaij, M. G., Bierings, R., Kragt, A., van Mourik, J. A., & Voorberg, J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209501.56852.6c · Cited by 344 · cited 1×
“Different stimuli can influence EC activation and can affect EC properties such as cell adhesion, cell shape, and immune function (Bach, Hancock, and Ferran 1997; Pober et al. 1990a; 1990b; Rondaij et al. 2006).”
BackgroundFrazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
Self-citationHARBOE, M., ULVUND, G., VIEN, L., FUNG, M., & MOLLNES, T. E. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02627.x · Cited by 319 · cited 1×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundEndothelium-derived nitric oxide and vascular physiology and pathology
Arnal, J.-F., Dinh-Xuan, A.-T., Pueyo, M., Darblade, B., & Rami, J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050358 · Cited by 313 · cited 1×
“Endothelial cells (ECs) lining vessels help to maintain the integrity of the vascular wall, participate in immune reactions via expression of adhesion molecules, and regulate local vascular tone by release of nitrous oxide (NO; Arnal et al. 1999).”
BackgroundCirculating markers of endothelial function in cardiovascular disease
Constans, J., & Conri, C. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.030 · Cited by 278 · cited 3×
“Initial activation/injury of the EC and persistent local inflammation is considered to contribute to vascular injury by a variety of means including those related to damage from cytokines, immune complexes, complement dysregulation, or T-cell activation (Blann et al. 2005; Constans and Conri 2006; Day, Hewins, and Sav…”
BackgroundPonce, R., Abad, L., Amaravadi, L., Gelzleichter, T., Gore, E., Green, J., Gupta, S., Herzyk, D., Hurst, C., Ivens, I. A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.03.012 · Cited by 270 · cited 1×
“Higher concentrations of antigen and antibody generally increase the risk for immune complex formation and vascular injury, but the amount and size of the complex or lattice depend on antigen to antibody ratios (Ponce et al. 2009).”
BackgroundMann, P. C., Vahle, J., Keenan, C. M., Baker, J. F., Bradley, A. E., Goodman, D. G., Harada, T., Herbert, R., Kaufmann, W., Kellner, R., et al. (2012) · Toxicologic Pathology · doi:10.1177/0192623312438738 · Cited by 241 · cited 3×
“The authors suggest the following current terminology guidelines set out in INHAND and Standard Exchange of Nonclinical Data (SEND) initiatives (Mann et al. 2012), using one or more of the preferred terms: artery, necrosis, medial; artery, inflammation, mural; artery, inflammation, perivascular;…”
BackgroundInfluentialProtective genes expressed in endothelial cells: a regulatory response to injury
Bach, F. H., Hancock, W. W., & Ferran, C. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01129-8 · Cited by 220 · cited 1×
“Different stimuli can influence EC activation and can affect EC properties such as cell adhesion, cell shape, and immune function (Bach, Hancock, and Ferran 1997; Pober et al. 1990a; 1990b; Rondaij et al. 2006).”
BackgroundKalled, S. L., Cutler, A. H., Datta, S. K., & Thomas, D. W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2158 · Cited by 199 · cited 1×
“…are many mouse models of vasculitis involving strains such as MRL/lpr, NZB, PN, and SNF1 (Holmes, and Burnet 1963, Luzina, Knitzer, and Atamas 1999, Kalled et al. 1998; Moyer, Strandberg, and Reinisch 1987) with lesions consisting of medial necrosis, and neutrophilic and/or mononuclear mural and…”
BackgroundLiu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6431 · Cited by 199 · cited 1×
“These aggregates can form during production or formulation of a biotherapeutic (Leach et al. 2014; Liu et al. 2011).”
BackgroundHOLMES, M. C., & BURNET, F. M. (1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-59-3-265 · Cited by 198
The Role of Microparticles in Inflammation and Thrombosis
Ardoin, S. P., Shanahan, J. C., & Pisetsky, D. S. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01984.x · Cited by 195 · cited 1×
“…have been seen in patients with vascular diseases, and may correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-George and Boulanger 2011; Erdbruegger et al. 2008, Erdbruegger,…”
BackgroundPendergraft, W. F., & Niles, J. L. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000014 · Cited by 183 · cited 1×
“…fully understood and the involvement of different factors such as drugs (e.g., prophylthiouracil, hydralazine, levamisol adulterated cocaine, D-penicillamine, and minocycline), environmental factors, infectious agents, and genetic background are considered important (Pendergraft and Niles 2014).”
BackgroundRalston, D. R., Marsh, C. B., Lowe, M. P., & Wewers, M. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119662 · Cited by 180 · cited 1×
“The binding of ANCA to primed leucocytes induces the production and release of many cytokines such as IL-1, MCP-1, and IL-8 (Berger et al. 1996; Brooks et al. 1996; Casselman et al. 1995; Ralston et al. 1997).”
BackgroundVascular Myofibroblasts: Lessons From Coronary Repair and Remodeling
Zalewski, A., & Shi, Y. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.3.417 · Cited by 178 · cited 1×
“Adventitial fibrosis and neovascularization can occur with chronic lesions, especially in large vessels, with differentiation of fibroblasts to myofibroblasts (Siow, Mallawaarachchi, and Weissberg 2003; Zalewski and Shi 1997).”
BackgroundEndothelial and platelet microparticles in vasculitis of the young
Brogan, P. A., Shah, V., Brachet, C., Harnden, A., Mant, D., Klein, N., & Dillon, M. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20199 · Cited by 176 · cited 1×
“…diseases, and may correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-George and Boulanger 2011; Erdbruegger et al. 2008, Erdbruegger, Dhaygude, and Woywodt 2011; Mesri and…”
BackgroundMechanisms of immune-deposit formation and the mediation of immune renal injury
Nangaku, M., & Couser, W. G. (2005) · Clinical and Experimental Nephrology · doi:10.1007/s10157-005-0357-8 · Cited by 164 · cited 1×
“Immune complexes differ in size and charge, and both may play a role in whether the immune complexes deposit in a tissue (Nangaku and Couser 2005).”
BackgroundImmunogenicity of therapeutic proteins: the use of animal models
Brinks, V., Jiskoot, W., & Schellekens, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0523-5 · Cited by 164 · cited 1×
“ADAs form relatively often in monkeys because recombinant human proteins are sufficiently different from homologous monkey proteins to result in immunogenicity (Brinks, Jiskoot, and Schellekens 2011; Leach et al. 2014; Rojko et al. 2014).”
BackgroundCirculating endothelial cells: life, death, detachment and repair of the endothelial cell layer
Woywodt, A., Bahlmann, F. H., Groot, K. D., Haller, H., & Haubitz, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.10.1728 · Cited by 164 · cited 1×
“Blood levels of CECs are increased in many conditions associated with endothelial dysfunction including hypertension, diabetes, preeclampsia, and chronic kidney failure (Boos et al. 2007; Canbakan et al. 2007; Koc, Bihorac, and Segal 2003; McClung et al. 2005; Woywodt et al. 2002).”
BackgroundMatrix Metalloproteinases as Novel Disease Markers in Takayasu Arteritis
Matsuyama, A., Sakai, N., Ishigami, M., Hiraoka, H., Kashine, S., Hirata, A., Nakamura, T., Yamashita, S., & Matsuzawa, Y. (2003) · Circulation · doi:10.1161/01.cir.0000090689.69973.b1 · Cited by 164
PATHOLOGY OF KAWASAKI DISEASE: I. PATHOLOGY AND MORPPHOGENESIS OF THE VASCULAR CHANGES
Amano, S., Hazama, F., & HAMASHIMA, Y. (1979) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.43.633 · Cited by 159
ANCA-associated vasculitides—advances in pathogenesis and treatment
Chen, M., & Kallenberg, C. G. M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.158 · Cited by 159 · cited 2×
“pathway of activation), as well as lymphocytes, are considered key events in AAV pathogenesis (Chen and Kallenberg 2010; Coughlan, Freeley, and Robson 2012; Jennette, Xiao, and Hu 2013; Kallenberg and Heeringa 2012; Radford, Lord, and Savage 1999).”
BackgroundVasodilator signals from perivascular adipose tissue
Gollasch, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01430.x · Cited by 157 · cited 1×
“The adventitia participates in inflammatory and proliferative responses and may also influence vascular damage through paracrine effects (Dalmas et al. 2011; Gollasch 2012).”
BackgroundRojko, J. L., Evans, M. G., Price, S. A., Han, B., Waine, G. J., DeWitte, M., Haynes, J. A., Freimark, B. D., Martin, P. L., Raymond, J. T., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314526475 · Cited by 157 · cited 15×
“Biotherapeutic-induced DIVI is most often attributable to immunogenicity of the drug and results in vasculitis through immune-mediated effects of cytokine release, complement fixation, and/or secondary thrombosis (Rojko et al. 2014).”
BackgroundInfluentialDrug-induced vasculitis: a clinical and pathological review.
Radić, M., Martinovic Kaliterna, D., & Radić, J. (2012) · PubMed · Cited by 153
McClung, J. A., Naseer, N., Saleem, M., Rossi, G. P., Weiss, M. B., Abraham, N. G., & Kappas, A. (2005) · Diabetologia · doi:10.1007/s00125-004-1647-5 · Cited by 145 · cited 1×
“Blood levels of CECs are increased in many conditions associated with endothelial dysfunction including hypertension, diabetes, preeclampsia, and chronic kidney failure (Boos et al. 2007; Canbakan et al. 2007; Koc, Bihorac, and Segal 2003; McClung et al. 2005; Woywodt et al. 2002).”
BackgroundReview article: Drug‐induced anti‐neutrophil cytoplasmic antibody‐associated vasculitis
Gao, Y., & Zhao, M. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01100.x · Cited by 144 · cited 2×
“Specific forms of human vascular injury are associated with ANCA antibodies, which involve direct activation of cytokineprimed neutrophils and monocytes and results in their degranulation and subsequent damage to the adjacent endothelium (Falk et al. 1990; Gao and Zhao 2009; Jennette, Falk, and Wilkman 1995; Radic, Ma…”
BackgroundTarrant, J. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq134 · Cited by 141 · cited 1×
“Tarrant, J. M. (2010). Blood cytokines as biomarkers of in vivo toxicity in”
BackgroundImmunogenicity of mAbs in non-human primates during nonclinical safety assessment
van Meer, P. J. K., Kooijman, M., Brinks, V., Gispen-de Wied, C. C., Silva-Lima, B., Moors, E. H. M., & Schellekens, H. (2013) · mAbs · doi:10.4161/mabs.25234 · Cited by 132 · cited 1×
“Importantly, ADA in the NHP does not consistently correlate with the occurrence of ADA to a biotherapeutic in humans (Van Meer et al. 2013).”
BackgroundFiler, A. D., Gardner-Medwin, J. M., Thambyrajah, J., Raza, K., Carruthers, D. M., Stevens, R. J., Liu, L., Lowe, S. E., Townend, J., & Bacon, P. A. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.2.162 · Cited by 132 · cited 1×
“…immune complexes, complement dysregulation, or T-cell activation (Blann et al. 2005; Constans and Conri 2006; Day, Hewins, and Savage 2003; Filer et al. 2003; Kollmeier et al. 1998; Langford 2003; Sibelius et al. 1998) as well as additional effects on leukocyte trafficking, vascular…”
BackgroundHIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
Kahook, M. Y., Liu, L., Ruzycki, P., Mandava, N., Carpenter, J. F., Petrash, J. M., & Ammar, D. A. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cea · Cited by 131
Leukocytoclastic vasculitis due to etanercept.
Galaria, N. A., Werth, V. P., & Schumacher, H. R. (2000) · PubMed · Cited by 130
Cell Signaling of Angiotensin II on Vascular Tone: Novel Mechanisms
Cat, A. N. D., & Touyz, R. M. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0187-x · Cited by 130 · cited 1×
“Smooth muscle cells (SMCs) regulate vascular tone and have receptors for endogenous vasoconstrictors such as angiotensin, endothelin, and epinephrine, and are also a target for NO and ion channel openers (Nguyen Dinh Cat and Touyz 2011; Galley and Webster 2004; Mehta and Griendling 2007).”
BackgroundBugelski, P. J., & Treacy, G. (2004) · PubMed · Cited by 130
Cellular and molecular effects of mechanical stretch on vascular cells and cardiac myocytes
Shyu, K.-G. (2009) · Clinical Science · doi:10.1042/cs20080163 · Cited by 125 · cited 1×
“They also synthesize anticoagulants, cytokines, and growth factors in response to vascular dynamics and shear stress (Annas and Brittebo 1998; Shyu 2009).”
BackgroundBrooks, C. J., King, W. J., Radford, D. J., Adu, D., McGrath, M., & Savage, C. O. S. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-835.x · Cited by 121 · cited 1×
“The binding of ANCA to primed leucocytes induces the production and release of many cytokines such as IL-1, MCP-1, and IL-8 (Berger et al. 1996; Brooks et al. 1996; Casselman et al. 1995; Ralston et al. 1997).”
BackgroundSharma, H. S., & Kiyatkin, E. A. (2009) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2008.08.002 · Cited by 118 · cited 1×
“Often, verification of EC injury or loss requires additional methods beyond routine histology (Lim, DeLano, and Schmid-Schonbein 2001; Mikaelian et al. 2010; Sharma and Kiyatkin 2009).”
MethodZhang, J., DeFelice, A. F., Hanig, J. P., & Colatsky, T. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378866 · Cited by 113 · cited 4×
“The activation of ECs causes an array of responses to biochemical and physical stimuli contributing to propagation of the immunological and inflammatory response (Zhang et al. 2010).”
BackgroundInfluentialDiagnostic role of endothelial microparticles in vasculitis
Erdbruegger, U., Grossheim, M., Hertel, B., Wyss, K., Kirsch, T., Woywodt, A., Haller, H., & Haubitz, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken373 · Cited by 113 · cited 2×
“…correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-George and Boulanger 2011; Erdbruegger et al. 2008, Erdbruegger, Dhaygude, and Woywodt 2011; Mesri and Altieri 1998; 1999).”
BackgroundSiow, R. C. M. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00292-x · Cited by 112 · cited 1×
“Adventitial fibrosis and neovascularization can occur with chronic lesions, especially in large vessels, with differentiation of fibroblasts to myofibroblasts (Siow, Mallawaarachchi, and Weissberg 2003; Zalewski and Shi 1997).”
BackgroundImmunogenicity/Hypersensitivity of Biologics
Leach, M. W., Rottman, J. B., Hock, M. B., Finco, D., Rojko, J. L., & Beyer, J. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313510987 · Cited by 106 · cited 3×
“ADAs form relatively often in monkeys because recombinant human proteins are sufficiently different from homologous monkey proteins to result in immunogenicity (Brinks, Jiskoot, and Schellekens 2011; Leach et al. 2014; Rojko et al. 2014).”
BackgroundSelf-citationUsui, T., Okada, M., Mizuno, W., Oda, M., Ide, N., Morita, T., Hara, Y., & Yamawaki, H. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01039.2011 · Cited by 99 · cited 2×
“…models of disease may also demonstrate vascular lesions without drug treatment, including spontaneous hypertensive rats (SHR) and various models of autoimmune disease (Amano, Hozama, and Hamaskima 1979; Brinks, Jiskoot, Schellekens 2011; Lim, DeLano, and Schmid- Schonbein 2001; Usui et al. 2012).”
BackgroundMerkel, P. A. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70239-8 · Cited by 98 · cited 1×
“Human DIVI may mimic a spectrum of spontaneous vascular diseases like PAN, Wegner’s granulomatosis, or Churg–Strauss syndrome (Doyle and Cuellar 2003; Merkel 2001; Radic, Martinovic Kaliterna, and Radic 2012), and in these cases can involve any type of artery, vein, or capillary including the aorta.”
BackgroundHarboe, M., Garred, P., Karlstrøm, E. S., Lindstad, J. K., Stahl, G. L., & Mollnes, T. E. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.09.005 · Cited by 92 · cited 1×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
BackgroundSato, J., Doi, T., Kanno, T., Wako, Y., Tsuchitani, M., & Narama, I. (2012) · Journal of Toxicologic Pathology · doi:10.1293/tox.25.63 · Cited by 90 · cited 2×
“syndromes involving multiple vessels are much less common (Chamanza et al. 2006; Sato et al. 2012).”
BackgroundImmunologic Mechanisms in Systemic Vasculitis
Conn, D. L., McDuffie, F. C., Holley, K. E., & Schroeter, A. E. (1976) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)05174-2 · Cited by 89 · cited 1×
“The etiology and pathogenesis of spontaneous vascular lesions in humans are not well understood but are believed to be immune mediated (Barron et al. 1988; Conn et al. 1976; Felsburg et al. 1992).”
BackgroundPathologic Features of Naturally Occurring Juvenile Polyarteritis in Beagle Dogs
Snyder, P. W., Kazacos, E. A., Scott‐Moncrieff, J. C., HogenEsch, H., Carlton, W. W., Glickman, L. T., & Felsburg, P. J. (1995) · Veterinary Pathology · doi:10.1177/030098589503200401 · Cited by 87 · cited 2×
“The so-called Beagle Pain Syndrome or canine juvenile polyarteritis syndrome (CJPS) occurs most often in young beagle dogs and shows similar inflammatory changes in vessels with consistent involvement of small- to medium-caliber cardiac, cranial mediastinal, and cervical meningeal vessels (Hayes, Roberts, and Halliwel…”
BackgroundMoyer, C. F., Strandberg, J. D., & Reinisch, C. L. (1987) · PubMed · Cited by 85
Rat histopathology: A glossary for use in toxicity and carcinogenicity studies
Greaves, P., & Faccini, J. M. (1984) · Cited by 84
Berger, S. P., Seelen, M. A., Hiemstra, P. S., Gerritsma, J. S. J., Heemskerk, E., van der Woude, F. J., & Daha, M. R. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75694 · Cited by 84
Drug-induced vascular injury—a quest for biomarkers
Expert Working Group on Drug-Induced Vascular Injury (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.08.001 · Cited by 82 · cited 5×
“…(PDE) 3 and 4 inhibitors, adenosine receptor agonists, dopaminergic agonists, endothelin receptor antagonists, angiotensin, bradykinin, a-adrenergic agonists, and Kir channel antagonists (Herman et al. 1989; Johansson 1981; W. Kerns et al. 2005; Losco et al. 2004; Mikaelian et al. 2014).”
BackgroundMethodInfluentialCross-talk between the complement and the kinin system in vascular permeability
Bossi, F., Peerschke, E. I. B., Ghebrehiwet, B., & Tedesco, F. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.06.006 · Cited by 80 · cited 1×
“Additionally, the kinin system can interact with ECs in induction of vascular leakage and, although the 2 systems may act independently, there is cross-talk, which involves different components of the complement and kinin systems (Bossi, Bulla and Tedesco 2008, Bossi et al. 2011; Volanakis 2014).”
BackgroundBl, C., Ks, K., Miller, B. F., & Warren, J. S. (1995) · PubMed · Cited by 80
Hart, S. P., Alexander, K. M., & Dransfield, I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1882 · Cited by 75 · cited 1×
“Immune complexes may also bind and deposit via CD32 expressed on inflammatory cells in monkeys, resulting in sequestration of neutrophils and monocytes in tissue capillaries and local cytokine release that may result in vascular damage (Hart, Alexander, and Dransfield 2004).”
BackgroundProperdin in complement activation and tissue injury
Lesher, A. M., Nilsson, B., & Song, W.-C. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.002 · Cited by 75 · cited 1×
“Properdin, a plasma glycoprotein, is the only currently known positive regulator of complement cascade and acts through stabilizing C3 convertase of the alternative pathway (Lesher, Nilsson, and Song 2013).”
BackgroundThe Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys
Losco, P. E., Evans, E. W., Barat, S., Blackshear, P. E., Reyderman, L., Fine, J. S., Bober, L. A., Anthes, J. C., Mirro, E. J., & Cuss, F. M. (2004) · Toxicologic Pathology · doi:10.1080/01926230490431493 · Cited by 75 · cited 3×
“Perivascular fibrosis with intimal and medial hypertrophy is noted chronically (Losco et al. 2004).”
BackgroundThe Impact of Immunosuppression on Endothelial Function
Trapp, A., & Weis, M. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200501000-00014 · Cited by 73
Radford, D. J., Lord, J. M., & Savage, C. O. S. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1999.01043.x · Cited by 70 · cited 1×
“…factors (especially those of the alternative pathway of activation), as well as lymphocytes, are considered key events in AAV pathogenesis (Chen and Kallenberg 2010; Coughlan, Freeley, and Robson 2012; Jennette, Xiao, and Hu 2013; Kallenberg and Heeringa 2012; Radford, Lord, and Savage 1999).”
BackgroundMonach, P. A., Tómasson, G., Specks, U., Stone, J. H., Cuthbertson, D. D., Krischer, J. P., Ding, L., Fervenza, F. C., Fessler, B. J., Hoffman, G. S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30615 · Cited by 69 · cited 1×
“Changes in other markers such as matrix metalloproteinases (MMP-1, MMP-3, and MMP-9), Vascular Endothelial Growth Factor, thrombomodulin, E-selectin, and P-selectin have been evaluated in human patients with vasculitis (Monach et al. 2011).”
BackgroundDoyle, M. K., & Cuellar, M. L. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.4.401 · Cited by 69 · cited 2×
“Many marketed drugs have been implicated with clinical DIVI, including small molecules and biotherapeutics (Doyle and Cuellar 2003; Radic, Martinovic Kaliterna, and Radic 2012; Taborda, Amaral, and Isenberg 2013).”
BackgroundTd, A., & Tj, H. (1989) · PubMed · Cited by 69
Pathogenesis of Cardiovascular Alterations in Dogs Treated with Minoxidil
Mesfin, G. M., Piper, R. C., DuCharme, D. W., Carlson, R. G., Humphrey, S. J., & Zins, G. R. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700113 · Cited by 69 · cited 1×
“…such as heart rate and blood pressure have been successfully used as surrogate biomarkers of DIVI for many small molecule drugs (W. D. Kerns, Arena, and Morgan 1989; W. D. Kerns et al. 1989; W. Kerns et al. 2005; Mesfin, Shawaryn, and Higgins 1987, Mesfin et al. 1989; 1996; Nyska et al. 1998).”
MethodAn Idiopathic Febrile Necrotizing Arteritis Syndrome in the Dog: Beagle Pain Syndrome,
Hayes, T. J., Roberts, G. K. S., & Halliwell, W. H. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700109 · Cited by 68 · cited 1×
“…polyarteritis syndrome (CJPS) occurs most often in young beagle dogs and shows similar inflammatory changes in vessels with consistent involvement of small- to medium-caliber cardiac, cranial mediastinal, and cervical meningeal vessels (Hayes, Roberts, and Halliwell 1989; Snyder et al. 1995).”
BackgroundPrimary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs
Mikaelian, I., Buneß, A., de Vera-Mudry, M.-C., Kanwal, C., Coluccio, D., Rasmussen, E., Char, H., Carvajal, V., Hilton, H., Funk, J., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq189 · Cited by 68 · cited 4×
“Often, verification of EC injury or loss requires additional methods beyond routine histology (Lim, DeLano, and Schmid-Schonbein 2001; Mikaelian et al. 2010; Sharma and Kiyatkin 2009).”
BackgroundMethodInfluentialSibelius, U., Hattar, K., Schenkel, A., Noll, T., Csernok, E., Gross, W. L., Mayet, W.-J., Piper, H. M., Seeger, W., & Grimminger, F. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.497 · Cited by 67 · cited 2×
“…and cell immune responses associated with EC injury (Blann et al. 2005, Constans and Conri 2006; Drouet et al. 2003; Kollmeier et al. 1998; Sibelius et al. 1998), several potential biomarkers for detecting DIVI have recently been proposed by these groups and lists of candidates are…”
BackgroundDereure, O., Navarro, R. P., Rossi, J., & Guilhou, J. (2001) · Dermatology · doi:10.1159/000051713 · Cited by 61 · cited 2×
“Clinical cases where marketed immunomodulatory biologics have induced vasculitis through cytokine-mediated pathways are also uncommon, but examples include reports with etanercept and rituximab (Dereure et al. 2001; Galaria, Werth, and Schumacher 2000).”
BackgroundWhere disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates
Demeule, B., Gurny, R., & Arvinte, T. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.08.008 · Cited by 59 · cited 1×
“…DIVI is often accompanied by the simultaneous occurrence of immunemediated glomerulonephritis (due to similar pathophysiologic mechanisms; Demeule, Gurny, and Arvinte 2006), proteinuria and/or albuminuria may be useful monitorable surrogate biomarkers for these effects (Frazier and Seely…”
BackgroundKoç, M., Bihorac, A., & Segal, M. S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00906-5 · Cited by 59 · cited 1×
“Blood levels of CECs are increased in many conditions associated with endothelial dysfunction including hypertension, diabetes, preeclampsia, and chronic kidney failure (Boos et al. 2007; Canbakan et al. 2007; Koc, Bihorac, and Segal 2003; McClung et al. 2005; Woywodt et al. 2002).”
BackgroundComplement in ANCA-Associated Vasculitis
Jennette, J. C., Xiao, H., & Hu, P. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.006 · Cited by 58 · cited 1×
“…factors (especially those of the alternative pathway of activation), as well as lymphocytes, are considered key events in AAV pathogenesis (Chen and Kallenberg 2010; Coughlan, Freeley, and Robson 2012; Jennette, Xiao, and Hu 2013; Kallenberg and Heeringa 2012; Radford, Lord, and Savage 1999).”
BackgroundEndothelial injury and repair in systemic vasculitis of the young
Clarke, L. A., Hong, Y., Eleftheriou, D., Shah, V., Arrigoni, F., Klein, N. J., & Brogan, P. A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27418 · Cited by 58 · cited 2×
“EMP can serve as surrogate markers of endothelial function and elevated levels of EMP have been seen in patients with vascular diseases, and may correspond to vascular injury in patients with cardiovascular disease and/ or vasculitis (Ardoin, Shanahan, and Pisetsky 2007; Brogan et al. 2004; Clarke et al. 2010; Dignat-…”
BackgroundSpontaneous Lesions of the Cardiovascular System in Purpose-Bred Laboratory Nonhuman Primates
Chamanza, R., Parry, N. M., Rogerson, P., Nicol, J. R., & Bradley, A. (2006) · Toxicologic Pathology · doi:10.1080/01926230600809737 · Cited by 58 · cited 2×
“syndromes involving multiple vessels are much less common (Chamanza et al. 2006; Sato et al. 2012).”
BackgroundDietsch, G. N., Dipalma, C. R., Eyre, R. J., Pham, T. Q., Poole, K. M., Pefaur, N. B., Welch, W. D., Trueblood, E., Kerns, W. D., & Kanaly, S. T. (2006) · Toxicologic Pathology · doi:10.1080/01926230500385549 · Cited by 55 · cited 2×
“The histologic lesions of small molecule–related DIVI have been well described (Dietsch et al. 2006; Hanton et al. 2008; Joseph, Rees, and Dayan 1996; Joseph 2000; W. D. Kerns, Arena, and Morgan 1989; C. Louden and Morgan 2001; Weaver et al. 2008; Yuhas et al. 1985), and include perivascular edema,…”
BackgroundAnimal models of antineutrophil cytoplasm antibody-associated vasculitis
Salama, A. D., & Little, M. A. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d2d52 · Cited by 55 · cited 1×
“Different animal models of vasculitis associated with ANCA antibodies have been developed where the production of autoantibodies against myeloperoxidase, proteinase-3, and other proteases was obtained in mice and rat (Coughlan, Freeley, and Robson 2012; Salama and Little 2012).”
BackgroundMartin, P. L., & Bugelski, P. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01812.x · Cited by 54 · cited 1×
“This reaffirms the often held contention that clinical immunemediated reactions are hard to predict from preclinical data (Bugelski and Tracy 2004; Martin and Bugelski 2012).”
BackgroundFelsburg, P. J., HogenEsch, H., Somberg, R. L., Snyder, P. W., & Glickman, L. T. (1992) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(92)90213-8 · Cited by 54 · cited 1×
“The etiology and pathogenesis of spontaneous vascular lesions in humans are not well understood but are believed to be immune mediated (Barron et al. 1988; Conn et al. 1976; Felsburg et al. 1992).”
BackgroundEngelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53 · cited 1×
“Vascular injury associated with antisense oligonucleotides is discussed in the companion to this article (Engelhardt et al. 2015).”
BackgroundSelf-citationToxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 52 · cited 3×
“Due to the relative specificity and receptor targeting of peptide therapies, off-target interactions are considered rare when compared to small molecules (Gribble et al. 2007).”
BackgroundInfluentialDifferentiating Spontaneous from Drug-Induced Vascular Injury in the Dog
Clemo, F. A. S., Evering, W., Snyder, P. W., & Albassam, M. (2003) · Toxicologic Pathology · doi:10.1080/01926230390174904 · Cited by 50 · cited 4×
“Many small molecule drugs are known to cause DIVI in preclinical species (Clemo et al. 2003; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; Zhang et al. 2008).”
BackgroundInfluentialBiomarkers of drug-induced vascular injury
Brott, D., Gould, S., Jones, H. B., Schofield, J., Prior, H. M., Valentin, J., Bjurström, S., Kenne, K., Schuppe‐Koistinen, I., & Katein, A. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.04.028 · Cited by 49 · cited 2×
“…utility has been limited by their potential qualification with only a very limited number of compounds, most of which are vasoactive molecules (Brott et al. 2005; Daguès, Pawlowski, Sobry, et al. 2007, Daguès, Pawlowski, Guigon, G, et al. 2007; Dalmas et al. 2008, 2011; Enerson et al. 2006;…”
BackgroundMechanisms of Adverse Drug Reactions to Biologics
Clarke, J. B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_16 · Cited by 48 · cited 1×
“ADAs have been a recurrent problem with protein-based biotherapeutics and typically occur within 10 to 14 days after initiation of dosing (Clarke 2010; Leach 2013).”
BackgroundBiomarkers and Mechanisms of Drug-Induced Vascular Injury in Non-Rodents
Louden, C. S., Brott, D., Katein, A., Kelly, T., Gould, S., Jones, H. B., Betton, G. R., Valetin, J.-P., & Richardson, R. J. (2006) · Toxicologic Pathology · doi:10.1080/01926230500512076 · Cited by 47 · cited 4×
“…Daguès, Pawlowski, Guigon, G, et al. 2007; Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010;…”
BackgroundInfluentialSelf-citationMikaelian, I., Cameron, M., Dalmas, D. A., Enerson, B. E., Gonzalez, R. J., Guionaud, S., Hoffmann, P. K., King, N. M. P., Lawton, M. P., Scicchitano, M. S., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314525686 · Cited by 46 · cited 11×
“The search for DIVI markers has been formalized, with the formation of a collaborative consortium of industry, academic, and regulatory experts into The Predictive Safety Testing Consortium (PSTC) Vascular Injury Working Group (VIWG), and a panel of biomarkers for DIVI has been proposed (Mikaelian et al. 2014).”
BackgroundInfluentialSelf-citationClinical and laboratory characteristics of drug-induced vasculitic syndromes.
Wiik, A. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1805 · Cited by 45 · cited 1×
“There are no specific histological features or laboratory tests to diagnose drugrelated vasculitis in man, but ANCA assays are generally performed, especially when small vessel vasculitis is suspected (Taborda, Amaral, and Isenberg 2013; Wiik 2005).”
BackgroundYuhas, E. M., Morgan, D., Arena, E., Kupp, R., Saunders, L., & Lewis, H. B. (1985) · PubMed · Cited by 44
Dhir, V., Fort, M., Mahmood, A., Higbee, R., Warren, W., Narayanan, P., & Wittman, V. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.613419 · Cited by 44 · cited 2×
“Other mAb therapeutics known to induce CRS or first infusion reactions include OKT3, Campath-1H, and Herceptin, but like TGN1412, these agents do not necessarily result in vasculitis or in direct injury to endothelium, and hence such agents should not be classified with others that may induce DIVI (Dhir et al. 2012).”
BackgroundSpontaneous Background Pathology in Göttingen Minipigs
Jeppesen, G., & Skydsgaard, M. (2015) · Toxicologic Pathology · doi:10.1177/0192623314538344 · Cited by 44 · cited 1×
“Spontaneous arteritis has been described in minipigs in multiple organs including mesentery, heart, lungs, spleen, pancreas, kidney, salivary glands, and both male and female reproductive tracts (Jeppesen and Skydsgaard 2014).”
BackgroundLangford, C. A., & MHS (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.80 · Cited by 44
A Comparative Study of Minoxidil-Induced Myocardial Lesions in Beagle Dogs and Miniature Swine
Herman, E. H., Ferrans, V. J., Young, R. S. K., & Balázs, T. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700114 · Cited by 43 · cited 2×
“…(PDE) 3 and 4 inhibitors, adenosine receptor agonists, dopaminergic agonists, endothelin receptor antagonists, angiotensin, bradykinin, a-adrenergic agonists, and Kir channel antagonists (Herman et al. 1989; Johansson 1981; W. Kerns et al. 2005; Losco et al. 2004; Mikaelian et al. 2014).”
BackgroundPatterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans
Greaves, P. (1998) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(98)80008-0 · Cited by 42 · cited 1×
“Hypertrophy and hyperplasia of SMCs occurs as a late stage vascular change and is often accompanied by intimal and adventitial fibrosis (Greaves 1998).”
BackgroundPathogenesis of Arterial Lesions Induced by Dopaminergic Compounds in the Rat
Kerns, W., Arena, E., Macia, R. A., Bugelski, P. J., Matthews, W. D., & Morgan, D. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700116 · Cited by 42 · cited 1×
“…such as heart rate and blood pressure have been successfully used as surrogate biomarkers of DIVI for many small molecule drugs (W. D. Kerns, Arena, and Morgan 1989; W. D. Kerns et al. 1989; W. Kerns et al. 2005; Mesfin, Shawaryn, and Higgins 1987, Mesfin et al. 1989; 1996; Nyska et al. 1998).”
MethodZhang, J., Herman, E. H., Robertson, D. G., Reily, M. D., Knapton, A. D., Ratajczak, H. V., Rifai, N., Honchel, R., Blanchard, K. T., Stoll, R. E., et al. (2006) · Toxicologic Pathology · doi:10.1080/01926230600588562 · Cited by 41 · cited 3×
“ECs have been previously shown to be activated by pharmacologic agents such as immunosuppressive drugs and vasoactive drugs (Joseph 2000; Trapp and Weiss 2005; Zhang, Herman, Knapton, et al. 2002, Zhang et al. 2006, 2008).”
BackgroundJoseph, E. C., Rees, J. A., & Dayan, A. D. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400406 · Cited by 41 · cited 5×
“…(Brott et al. 2005; Daguès, Pawlowski, Sobry, et al. 2007, Daguès, Pawlowski, Guigon, G, et al. 2007; Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas…”
BackgroundInfluentialZhang, J., Herman, E. H., Knapton, A. D., Chadwick, D. P., Whitehurst, V. E., Koerner, J. E., Papoian, T., Ferrans, V. J., & Sistare, F. D. (2002) · Toxicologic Pathology · doi:10.1080/01926230252824680 · Cited by 40 · cited 2×
“Fulminant lesions can be observed as soon as 12 hr (Zhang et al., 2002a), but more typically several days of dosing are required to induce the full spectrum of morphologic changes (Zhang et al. 2008).”
BackgroundMechanisms of tissue deposition of immune complexes.
Mannik, M. (1987) · PubMed · Cited by 39
Complement is crucial in the pathogenesis of ANCA-associated vasculitis
Kallenberg, C. G. M., & Heeringa, P. (2012) · Kidney International · doi:10.1038/ki.2012.371 · Cited by 39 · cited 2×
“pathway of activation), as well as lymphocytes, are considered key events in AAV pathogenesis (Chen and Kallenberg 2010; Coughlan, Freeley, and Robson 2012; Jennette, Xiao, and Hu 2013; Kallenberg and Heeringa 2012; Radford, Lord, and Savage 1999).”
BackgroundAbnormalities of immunoregulation in Kawasaki syndrome.
Barron, K. S., Decunto, C. L., Montalvo, J., Orson, F. M., & Lewis, D. (1988) · PubMed · Cited by 39
Dubost, J., Souteyrand, P., & Sauvezie, B. (1991) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(05)80299-7 · Cited by 38
Daguès, N., Pawlowski, V., Sobry, C., Hanton, G. C., Borde, F., Soler, S., Freslon, J., & Chevalier, S. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm161 · Cited by 37
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
Minor, D. R., Bunker, S. R., & Doyle, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5095 · Cited by 37 · cited 2×
“Some patients have shown autoimmune antibody titers and infiltrates of lymphocytes within and around vessels in various organs including gastrointestinal tract, pancreas, and reproductive tracts (Minor, Bunker, and Doyle 2013).”
BackgroundNew developments in the pathogenesis of ANCA-associated vasculitis.
Day, C., Hewins, P., & Savage, C. O. S. (2003) · PubMed · Cited by 36
Collins, J. J., Elwell, M. R., Lamb, J. C., Manus, A. G., Heath, J. E., & Makovec, G. T. (1988) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(88)90111-x · Cited by 36
Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA1 agonists
Joseph, E. C. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00221-0 · Cited by 35 · cited 5×
“ECs have been previously shown to be activated by pharmacologic agents such as immunosuppressive drugs and vasoactive drugs (Joseph 2000; Trapp and Weiss 2005; Zhang, Herman, Knapton, et al. 2002, Zhang et al. 2006, 2008).”
BackgroundInfluentialLuzina, I. G., Knitzer, R. H., Atamas, S. P., Gause, W. C., Papadimitriou, J. C., Sztein, M. B., Storrer, C. E., & Handwerger, B. S. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199904)42:3<527::aid-anr18>3.0.co;2-m · Cited by 35
Cardiovascular Alterations in Dogs Treated with Hydralazine
Mesfin, G. M., Shawaryn, G. G., & Higgins, M. J. (1987) · Toxicologic Pathology · doi:10.1177/019262338701500404 · Cited by 35 · cited 1×
“…such as heart rate and blood pressure have been successfully used as surrogate biomarkers of DIVI for many small molecule drugs (W. D. Kerns, Arena, and Morgan 1989; W. D. Kerns et al. 1989; W. Kerns et al. 2005; Mesfin, Shawaryn, and Higgins 1987, Mesfin et al. 1989; 1996; Nyska et al. 1998).”
MethodMesfin, G. M., Higgins, M. J., Robinson, F. G., & Zhong, W.-Z. (1996) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.0229 · Cited by 35 · cited 2×
“Despite extensive efforts to define the relevance of DIVI in preclinical studies to humans, and to identify biomarkers for vascular injury across species, the translatability of DIVI from animals to humans remains unclear (Mesfin et al. 1996).”
BackgroundMethodLouden, C. S., & Morgan, D. (2001) · Pharmacology & Toxicology · doi:10.1111/j.0901-9928.2001.890404.x · Cited by 34 · cited 1×
“…have been well described (Dietsch et al. 2006; Hanton et al. 2008; Joseph, Rees, and Dayan 1996; Joseph 2000; W. D. Kerns, Arena, and Morgan 1989; C. Louden and Morgan 2001; Weaver et al. 2008; Yuhas et al. 1985), and include perivascular edema, inflammatory cell infiltrates (frequently including…”
BackgroundSelf-citationHeyen, J. R. R., Rojko, J. L., Evans, M. G., Brown, T. P., Bobrowski, W. F., Vitsky, A., Dalton, S., Tripathi, N., Bollini, S. S., Johnson, T., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314522559 · Cited by 34 · cited 3×
“During 2 separate 6-month duration toxicity studies, immune complex–mediated vasculitis was noted following administration of RN6G (Heyen et al. 2014).”
BackgroundMethodInfluentialBoos, C. J., Lane, D. A., Karpha, M., Beevers, D. G., Haynes, R., & Lip, G. Y. H. (2007) · CHEST Journal · doi:10.1378/chest.07-0428 · Cited by 34 · cited 1×
“Blood levels of CECs are increased in many conditions associated with endothelial dysfunction including hypertension, diabetes, preeclampsia, and chronic kidney failure (Boos et al. 2007; Canbakan et al. 2007; Koc, Bihorac, and Segal 2003; McClung et al. 2005; Woywodt et al. 2002).”
BackgroundCARDIOVASCULAR LESIONS IN SPRAGUE‐DAWLEY RATS INDUCED BY LONG‐TERM TREATMENT WITH CAFFEINE
Johansson, S. L. (1981) · Acta Pathologica Microbiologica Scandinavica Section A Pathology · doi:10.1111/j.1699-0463.1981.tb00207.x · Cited by 33 · cited 2×
“…(PDE) 3 and 4 inhibitors, adenosine receptor agonists, dopaminergic agonists, endothelin receptor antagonists, angiotensin, bradykinin, a-adrenergic agonists, and Kir channel antagonists (Herman et al. 1989; Johansson 1981; W. Kerns et al. 2005; Losco et al. 2004; Mikaelian et al. 2014).”
BackgroundPolyarteritis Nodosa in a Cynomolgus Macaque (Macaca fascicularis)
Porter, B. F., Frost, P., & Hubbard, G. B. (2003) · Veterinary Pathology · doi:10.1354/vp.40-5-570 · Cited by 33 · cited 1×
“In a case report involving an untreated cynomolgus macaque (Porter, Frost, and Hubbard 2003), small- to medium-caliber arteries in the kidney, small intestine, colon, heart, spleen, mesentery, urinary bladder, and pancreas had varying degrees of inflammation.”
BackgroundLand, J., Rutgers, A., & Kallenberg, C. G. M. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft416 · Cited by 33 · cited 1×
“…is still under debate due to the observation that natural ANCA against myeloperoxidase and proteinase-3 can occur in healthy individuals, the lack of strong correlation between ANCA titer and disease activity, and the occurrence of ANCA-negative AAV patients (Land, Rutgers, and Kallenberg 2014).”
BackgroundKerns, W., Arena, E., & Morgan, D. (1989) · PubMed · Cited by 33
Comparison of vascular leak syndrome in mice treated with IL21 or IL2.
Sivakumar, P. V., García, R., Waggie, K. S., Anderson-Haley, M., Nelson, A., & Hughes, S. D. (2013) · Europe PMC (PubMed Central) · Cited by 32
Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis
Coughlan, A. M., Freeley, S. J., & Robson, M. G. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04616.x · Cited by 32
Experimental immune complex-mediated glomerulonephritis in the nonhuman primate
Hebert, L. A., Cosio, F. G., Birmingham, D. J., Mahan, J. D., Sharma, H. M., Smead, W. L., & Goel, R. (1991) · Kidney International · doi:10.1038/ki.1991.6 · Cited by 32 · cited 1×
“These factors may increase the risk for drug-related immune complex persistence in serum (Alexander, Clarkson, and Fulgham 1985; Hebert et al. 1991, 1994).”
BackgroundEndothelial cells are a target of both complement and kinin system
Bossi, F., Bulla, R., & Tedesco, F. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.08.006 · Cited by 32
Zhang, J., Hanig, J. P., & Felice, A. F. D. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.09.002 · Cited by 31 · cited 1×
“…Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008; 2012).”
Wu, H., Chen, H., & Hu, P. C. (2007) · PubMed · Cited by 30
Life and Death Cell Labeling in the Microcirculation of the Spontaneously Hypertensive Rat
Lim, H. H., DeLano, F. A., & Schmid‐Schönbein, G. W. (2001) · Journal of Vascular Research · doi:10.1159/000051051 · Cited by 30 · cited 1×
“Often, verification of EC injury or loss requires additional methods beyond routine histology (Lim, DeLano, and Schmid-Schonbein 2001; Mikaelian et al. 2010; Sharma and Kiyatkin 2009).”
MethodSafety Evaluation of Recombinant Human Interleukin-4
Leach, M. W., Snyder, E. A., Sinha, D. P., & Rosenblum, I. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4303 · Cited by 30 · cited 2×
“…IL-4 (rhuIL-4), a potent immune stimulator targeting cancer, induced dose-dependent proliferative and inflammatory vascular changes centered on arteries in multiple organs when given to monkeys for 1 month by daily subcutaneous injection (Barbolt, Gossett, and Cornacoff 1991; Leach et al. 1997).”
BackgroundSelf-citationAcute Drug-Induced Vascular Injury in Beagle Dogs: Pathology and Correlating Genomic Expression
Enerson, B. E., Lin, A., Lü, B., Zhao, H., Lawton, M. P., & Floyd, E. (2006) · Toxicologic Pathology · doi:10.1080/01926230500512068 · Cited by 30 · cited 1×
“…vasoactive molecules (Brott et al. 2005; Daguès, Pawlowski, Sobry, et al. 2007, Daguès, Pawlowski, Guigon, G, et al. 2007; Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001;…”
Albassam, M., Metz, A. L., Gragtmans, N. J., King, L. M., Macallum, G. E., Hallak, H., & McGuire, E. J. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700202 · Cited by 30 · cited 3×
“In most types of vascular injury in laboratory animals, mixed inflammatory cell infiltrates are most common and may include macrophages, neutrophils (Albassam et al. 1999; C. S. Louden et al. 2000; Joseph, Rees, and Dayan 1996), eosinophils (Anderson and Hayes 1989; Bregman et al. 1987), and…”
BackgroundZhang, J., Snyder, R. D., Herman, E. H., Knapton, A. D., Honchel, R., Miller, T. J., Espandiari, P., Goodsaid, F. M., Rosenblum, I. Y., Hanig, J. P., et al. (2008) · Toxicologic Pathology · doi:10.1177/0192623308322308 · Cited by 30 · cited 7×
“ECs have been previously shown to be activated by pharmacologic agents such as immunosuppressive drugs and vasoactive drugs (Joseph 2000; Trapp and Weiss 2005; Zhang, Herman, Knapton, et al. 2002, Zhang et al. 2006, 2008).”
BackgroundInfluentialSelf-citationEvaluation of Plasma von Willebrand Factor as a Biomarker for Acute Arterial Damage in Rats
Newsholme, S. J., Thudium, D. T., Gossett, K. A., Watson, E. S., & Schwartz, L. W. (2000) · Toxicologic Pathology · doi:10.1177/019262330002800508 · Cited by 29 · cited 2×
“…Guigon, G, et al. 2007; Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b;…”
BackgroundWestwood, F. R. (1990) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(90)90304-3 · Cited by 29 · cited 2×
“Chronic administration of these vasoactive agents may result in extensive acute lesions (Westwood, Iswaran, and Greaves 1990) or lesions similar to those observed in spontaneous lesions of polyarteritis nodosa (PAN).”
BackgroundTheophylline-induced mesenteric periarteritis in F344/N rats
Nyska, A., Herbert, R. A., Chan, P. C., Haseman, J. K., & Hailey, J. R. (1998) · Archives of Toxicology · doi:10.1007/s002040050567 · Cited by 28
Weaver, J. L., Snyder, R. D., Knapton, A. D., Herman, E. H., Honchel, R., Miller, T. J., Espandiari, P., Smith, R., Gu, Y., Goodsaid, F. M., et al. (2008) · Toxicologic Pathology · doi:10.1177/0192623308322310 · Cited by 28 · cited 2×
“…Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008; 2012).”
BackgroundSelf-citationMorton, D. G., Safron, J. A., Glosson, J., Rice, D., Wilson, D. M., & White, R. D. (1997) · Toxicologic Pathology · doi:10.1177/019262339702500407 · Cited by 28 · cited 1×
“Hypertrophy and hyperplasia of ECs may be a primary change or occur later in the time course of vascular injury following EC loss (Morton et al. 1997).”
BackgroundAlbassam, M., Metz, A. L., Potoczak, R. E., Gallagher, K. P., Haleen, S. J., Hallak, H., & McGuire, E. J. (2001) · Toxicologic Pathology · doi:10.1080/019262301316905228 · Cited by 27 · cited 1×
“However, not all small molecules that are associated with DIVI alter clinically measurable hemodynamic parameters (Albassam et al. 1999, 2001; Dalmas et al. 2011; Jones et al. 2003).”
BackgroundCirculating endothelial cells in preeclampsia
Canbakan, B., Keven, K., Tutkak, H., Danışman, N., Ergün, İ., & Nergızoğlu, G. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002199 · Cited by 26 · cited 1×
“Blood levels of CECs are increased in many conditions associated with endothelial dysfunction including hypertension, diabetes, preeclampsia, and chronic kidney failure (Boos et al. 2007; Canbakan et al. 2007; Koc, Bihorac, and Segal 2003; McClung et al. 2005; Woywodt et al. 2002).”
BackgroundImmune Complexes in Systemic Lupus Erythematosus
Wener, M. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00026-7 · Cited by 25 · cited 1×
“When biotherapeutics are injected, an antibody response may be generated in the monkey, and immune complexes of various sizes can form (Wener 2007).”
Background[Pathology of Kawasaki disease].
Shirai, N., Yabana, T., & Ueda, M. (2008) · PubMed · Cited by 24
Annas, A., & Brittebo, E. B. (1998) · Toxicology · doi:10.1016/s0300-483x(98)00087-0 · Cited by 24 · cited 1×
“They also synthesize anticoagulants, cytokines, and growth factors in response to vascular dynamics and shear stress (Annas and Brittebo 1998; Shyu 2009).”
BackgroundEndothelin Receptor Subtype Distribution Predisposes Coronary Arteries to Damage
Louden, C. S., Nambi, P., Pullen, M. A., Thomas, R. A., Tierney, L. A., Solleveld, H. A., & Schwartz, L. W. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64524-5 · Cited by 24 · cited 1×
“…vascular injury in laboratory animals, mixed inflammatory cell infiltrates are most common and may include macrophages, neutrophils (Albassam et al. 1999; C. S. Louden et al. 2000; Joseph, Rees, and Dayan 1996), eosinophils (Anderson and Hayes 1989; Bregman et al. 1987), and lymphocytes (Figure 1).”
BackgroundSelf-citationProbable grade IV dextran-induced anaphylactic reaction despite hapten inhibition
Bircher, A. J., Hédin, H., & Berglund, A. (1995) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(95)70327-6 · Cited by 24 · cited 1×
“For instance, immune complex reactions have resulted rarely from dextran infusion in clinical patients with high antidextran IgG levels (Bircher, Hedin, and Berglund 1995).”
BackgroundPotential candidate genomic biomarkers of drug induced vascular injury in the rat
Dalmas, D. A., Scicchitano, M. S., Mullins, D., Hughes‐Earle, A., Tatsuoka, K. S., Magid-Slav, M., Frazier, K. S., & Thomas, H. C. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.09.015 · Cited by 23 · cited 3×
“The adventitia participates in inflammatory and proliferative responses and may also influence vascular damage through paracrine effects (Dalmas et al. 2011; Gollasch 2012).”
BackgroundSelf-citationDalmas, D. A., Scicchitano, M. S., Chen, Y., Kane, J., Mirabile, R. C., Schwartz, L. W., Thomas, H. C., & Boyce, R. W. (2008) · Toxicologic Pathology · doi:10.1177/0192623307311400 · Cited by 23 · cited 2×
“…biomarkers have included factors involved in EC activation (Zhang et al. 2010), edema, inflammation, tissue remodeling, (Blake, and Ridker 2001; Dalmas et al. 2008; Daguès, Pawlowski, Guigon, et al. 2007; Daguès, Pawlowski, Sobry, et al. 2007) and maintenance of vascular tone (C. Louden et…”
BackgroundSelf-citationDetection and characterization of circulating endothelial progenitor cells in normal rat blood
Thomas, R. A., Pietrzak, D. C., Scicchitano, M. S., Thomas, H. C., McFarland, D. C., & Frazier, K. S. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.06.002 · Cited by 22 · cited 5×
“Circulating endothelial cells (CEC) have also been proposed as biomarkers of DIVI (Thomas et al. 2009) and are thought to be detached following injury and hence detectable in the peripheral circulation.”
BackgroundMethodInfluentialSelf-citationEndothelin Antagonist-Induced Coronary and Systemic Arteritis in the Beagle Dog
Macpherson, A., Betton, G. R., Davis, A. S., Robert, S., Greaves, P., & Greaves, P. (2003) · Toxicologic Pathology · doi:10.1080/01926230390204298 · Cited by 22 · cited 1×
“However, not all small molecules that are associated with DIVI alter clinically measurable hemodynamic parameters (Albassam et al. 1999, 2001; Dalmas et al. 2011; Jones et al. 2003).”
BackgroundLeach, M. W. (2013) · Toxicologic Pathology · doi:10.1177/0192623312451371 · Cited by 22
Self-citationTranslation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers
Bendjama, K., Guionaud, S., Aras, G., Arber, N., Badimón, L., Bamberger, U., Bratfalean, D., Brott, D., David, M., Doessegger, L., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314527644 · Cited by 21 · cited 8×
“Since there have been several recent reviews of potential biomarkers for DIVI (Bendjama et al. 2014; C. Louden et al. 2006; Mikaelian et al. 2014; Zhang et al. 2010), this article will only briefly summarize work in vascular biomarkers related to small molecule development and will instead focus on recent biomarkers n…”
BackgroundInfluentialSelf-citationAsymptomatic polyarteritis in a cynomolgus monkey.
Albassam, M., Lillie, L. E., & Smith, G. (1993) · PubMed · Cited by 21
Daguès, N., Pawlowski, V., Guigon, G., Ledieu, D., Sobry, C., Hanton, G. C., Freslon, J., & Chevalier, S. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.10.018 · Cited by 20
Systemic administration of an Fcγ–Fcε-fusion protein in house dust mite sensitive nonhuman primates
Scott, M. R. V., Mertsching, E., Negrou, E., Miles, J. J., Stallings, H. W., Graff, C. L., & Kehry, M. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.05.001 · Cited by 19 · cited 1×
“Type I (IgE-mediated) hypersensitivities may also occur after biotherapeutic administration in monkeys (Van Scott et al. 2008), but these generally do not manifest as vascular injury.”
BackgroundDrouet, C., Nissou, M.-F., Ponard, D., Arvieux, J., Dumestre‐Pérard, C., Gaudin, P., Imbert, B., Massot, C., & Sarrot-Reynauld, F. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.5.934-939.2003 · Cited by 18 · cited 2×
“…of complement activation, T cell activation, and cell immune responses associated with EC injury (Blann et al. 2005, Constans and Conri 2006; Drouet et al. 2003; Kollmeier et al. 1998; Sibelius et al. 1998), several potential biomarkers for detecting DIVI have recently been proposed by…”
BackgroundSafety Evaluation of Recombinant Human Interleukin-4
Leach, M. W., Rybak, M. E., & Rosenblum, I. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4304 · Cited by 18 · cited 2×
“The authors concluded that rhuIL-4-related lesions resulted from activation of the immune system and secondary effects on ECs (Leach, Rybak, and Rosenblum 1997), and the rhuIL-4-related clinico-pathological changes were considered to be reversible (Gossett et al. 1993).”
BackgroundSelf-citationRojko, J. L., & Price‐Schiavi, S. A. (2007) · Wiley eBooks · doi:10.1002/9780470292549.ch11 · Cited by 18
Single-dose and multiple-dose intravenous toxicity studies of BMY-25282 in rats
Bregman, C. L. (1987) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(87)90157-6 · Cited by 17 · cited 3×
“An example is the multiorgan endothelial injury due to anticancer drugs (Bregman et al. 1987; Mikaelian et al. 2010), and features will be described later in this article as they apply to relevant biotherapeutics.”
BackgroundEarly Events in Vascular Injury in the Rat Induced by the Phosphodiesterase IV Inhibitor SCH 351591
Weaver, J. L., Zhang, J., Knapton, A. D., Miller, T. J., Espandiari, P., Smith, R., Gu, Y., & Snyder, R. D. (2010) · Toxicologic Pathology · doi:10.1177/0192623310374331 · Cited by 16 · cited 1×
“…Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008; 2012).”
Self-citationHanton, G. C., Sobry, C., Daguès, N., Provost, J.-P., Net, J.-L. L., Comby, P., & Chevalier, S. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.03.009 · Cited by 15 · cited 1×
“The histologic lesions of small molecule–related DIVI have been well described (Dietsch et al. 2006; Hanton et al. 2008; Joseph, Rees, and Dayan 1996; Joseph 2000; W. D. Kerns, Arena, and Morgan 1989; C. Louden and Morgan 2001; Weaver et al. 2008; Yuhas et al. 1985), and include perivascular edema,…”
BackgroundHuman Hypersensitivity Angiitis, An Immune Complex Disease
SAMS, W. M. (1985) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12275678 · Cited by 14 · cited 1×
“There are a number of other inflammatory markers that may be of relevance to biotherapeutic-associated DIVI due to their pathogenesis involving immune deposition (Sams 1985).”
BackgroundStills, H. F., Bc, B., & Tb, C. (1983) · PubMed · Cited by 13
Stagliano, N. E., Carpino, A., Ross, J. S., & Donovan, M. J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03960.x · Cited by 13 · cited 2×
“…2007; Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008;…”
BackgroundSPONTANEOUS OCCURRENCE OF VASCULITIS-LIKE LESIONS IN MALE REPRODUCTIVE TISSUES
Itoh, M., MIYAMOTO, K., Tatsujiroh, O. H. G. A., & Takeuchi, Y. (1999) · Archives of Andrology · doi:10.1080/014850199262814 · Cited by 12 · cited 1×
“Spontaneous vascular lesions have also been seen in the epididymis and vas deferens in aging BALB/c mice and are of unknown pathogenesis (Itoh et al. 1999).”
BackgroundBarbolt, T. A., Gossett, K. A., & Cornacoff, J. B. (1991) · Toxicologic Pathology · doi:10.1177/019262339101900307 · Cited by 11 · cited 1×
“…IL-4 (rhuIL-4), a potent immune stimulator targeting cancer, induced dose-dependent proliferative and inflammatory vascular changes centered on arteries in multiple organs when given to monkeys for 1 month by daily subcutaneous injection (Barbolt, Gossett, and Cornacoff 1991; Leach et al. 1997).”
BackgroundThe Role of eNOS Phosphorylation in Causing Drug-induced Vascular Injury
Tobin, G. A. M., Zhang, J., Goodwin, D., Stewart, S. R., Xu, L., Knapton, A. D., González, C., Bancos, S., Zhang, L. W., Lawton, M. P., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314522885 · Cited by 11 · cited 1×
“Many drugs also have signaling pathways that can pass through endothelial nitric oxide synthase (eNOS), and modulation of NO production can affect lesion severity (Tobin et al. 2014).”
BackgroundSelf-citationAnti-neutrophil cytoplasmic autoantibodies--a serologic marker for vasculitides.
Jennette, J. C., Falk, R. J., & Wilkman, A. S. (1995) · PubMed · Cited by 11
Rojko, J. L., & Price‐Schiavi, S. A. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse170 · Cited by 10 · cited 2×
“Several other examples of immune complex–related vasculitis with therapeutic mAbs have been documented using immunohistochemistry (Rojko and Price-Schiavi 2008; Rojko et al. 2014).”
BackgroundKorkmaz, S., Maupoil, V., Sobry, C., Brunet, C., Chevalier, S., & Freslon, J. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn218 · Cited by 10
Functional properties of antiendothelial cell antibodies
Kollmeier, A. P., Kreditor, M., George, J., Levy, Y. M., & Shoenfeld, Y. (1998) · Clinical Reviews in Allergy & Immunology · doi:10.1007/bf02737639 · Cited by 10 · cited 2×
“…complement dysregulation, or T-cell activation (Blann et al. 2005; Constans and Conri 2006; Day, Hewins, and Savage 2003; Filer et al. 2003; Kollmeier et al. 1998; Langford 2003; Sibelius et al. 1998) as well as additional effects on leukocyte trafficking, vascular permeability, and…”
BackgroundHebert, L. A., Birmingham, D. J., Shen, X. P., Cosío, B. G., & Fryczkowski, A. (1994) · Journal of the American Society of Nephrology · doi:10.1681/asn.v55s70 · Cited by 10
MicroRNA changes in rat mesentery and serum associated with drug-induced vascular injury
Thomas, R. A., Scicchitano, M. S., Mirabile, R. C., Chau, N. T., Frazier, K. S., & Thomas, H. C. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.05.009 · Cited by 9 · cited 2×
“…Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008; 2012).”
BackgroundSelf-citationBiasucci, L. M., & Cardillo, M. T. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.12.003 · Cited by 9 · cited 1×
“In humans, DIVI accounts for about 3% of all vasculitides (Biasucci and Cardillo 2012), and the skin and kidneys are most frequently affected.”
BackgroundGossett, K. A., Barbolt, T. A., Cornacoff, J. B., Zelinger, D. J., & Dean, J. H. (1993) · Toxicologic Pathology · doi:10.1177/019262339302100106 · Cited by 9 · cited 1×
“The authors concluded that rhuIL-4-related lesions resulted from activation of the immune system and secondary effects on ECs (Leach, Rybak, and Rosenblum 1997), and the rhuIL-4-related clinico-pathological changes were considered to be reversible (Gossett et al. 1993).”
BackgroundCirculating immune complexes in cynomolgus macaques.
Alexander, N. J., Clarkson, T. B., & Fulgham, D. L. (1985) · PubMed · Cited by 9
Immune Complexes in Systemic Lupus Erythematosus
Wener, M. H. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-04434-9.50026-9 · Cited by 9
Taborda, L., Amaral, B., & Isenberg, D. A. (2013) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0b013e32836106df · Cited by 4
Carlton, W. W., & Engelhardt, J. A. (1991) · Monographs on pathology of laboratory animals · doi:10.1007/978-3-642-76533-9_13 · Cited by 4
Self-citationHemodynamics in the Determination of Endothelial Phenotype and Flow Mechanotransduction
Davies, P. F. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511546198.029 · Cited by 3 · cited 2×
“EC activation refers to the profound and diverse changes in EC phenotype (i.e., hypertrophy, protrusion into the vascular lumen, and immunohistochemical marker expression) in response to different cytokines, as well as the response to external mechanical forces (Davies 2007; Pober et al. 1990a).”
BackgroundEndothelium and the Initiation of Atherosclerosis
Cybulsky, M. I. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511546198.133 · Cited by 2 · cited 1×
“…tumor necrosis factor (TNF) a, can activate ECs and modulate their phenotype by inducing the expression of cell surface markers (i.e., E-Selectin, P-Selectin, vascular cell adhesion molecule [VCAM] 1, and intercellular adhesion molecule [ICAM] 1) promoting leukocyte interactions (Cybulsky 2007).”
BackgroundIn Search of Biomarkers for Drug‐Induced Vascular Injury
Turk, J. R. (2010) · Wiley eBooks · doi:10.1002/9780470918562.ch11 · Cited by 1 · cited 2×
“…Dalmas et al. 2008, 2011; Enerson et al. 2006; Joseph, Rees, and Dayan 1996; W. Kerns et al. 2005; C. Louden et al. 2006; Newsholme et al. 2000; Stagliano et al. 2001; Thomas et al. 2009; Thomas et al. 2012; Turk 2010; Weaver et al. 2008; 2010; Zhang et al., 2002b; Zhang et al. 2006; 2008; 2012).”
BackgroundVolanakis, J. E. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199659869.003.0005 · Cited by 1 · cited 3×
“General details on specific complement biology will not be reviewed in this article but can be found in relevant review articles (Harboe et al. 2004, 2009; Noris and Remuzzi 2013; Ricklin et al. 2010; Ricklin and Lambris 2013; Volanakis 2014).”
Background
Research works printed but not linked: 34
- Albassam M. A., 1993, Lab Anim Sci, 43, 628
- Alexander N. J., 1985, Lab Anim Sci, 35, 465
- Alpers C. E., 2009, Pathologic Basis of Disease, Professional Edition, 930
- Anderson T. D., 1989, Lab Invest, 60, 331
- Barron K., 1988, J Rheumatol, 15, 1243
- Blann A. D., 2005, Thromb Haemost, 3, 228
- Bugelski P. J., 2004, Curr Opin Mol Ther, 6, 10
- Casselman B. L., 1995, J Lab Clin Med, 126, 495
- Cines D. B., 1998, Blood, 91, 3527
- Conn D. L., 1976, Mayo Clin Proc, 56, 511
- Daguès N., 2007, Toxicol Sci, 107, 298
- Day C. J., 2003, Clin Exp Rheumatol, 21, S35
- Dhir V., 2012, J Immunol, 9, 34
- Enerson B., 2010, Toxicologist, 114, 7
- Erdbruegger U., Dhaygude A., Woywodt A. (2011). Markers of Vascular Damage and Repair, Advances in the Etiology, Pathogenesis and Pathology of Vasculitis (Amezcua-Guerra Luis M.Dr, ed.), pp. 179–94. Elsevier, ISBN: 978-953-307-651-5.
- Frazier K. S., 2014, Toxicol Pathol
- Frazier K. S., 2013, Toxicologic Pathology: Preclinical Safety Assessment, 426
- Galaria N. A., 2000, J Rheumatol, 27, 2041
- Gimbrone M. A., 1997, J Clin Invest, 100, S61
- Jeppesen G., 2014, Toxicol Pathol, 42
- Jennette J. C., 1995, Ann Acad Med Singapore, 24, 248
- Johansson S., 1981, Acta Path Microbial Scand Sect A, 89, 185
- Kerns W. D., 1989, Am J Pathol, 135, 339
- Kumar V., 2010, Robbins and Cotran Pathologic Basis of Diseaes, 183
- 10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x · doi:10.1002/1529-0131(199904)42:3<561::aid-anr22>3.0.co;2-x
- Mannik M., 1987, J Rheumatol, 14, 35
- Moyer C. F., 1987, Am J Pathol, 127, 229
- Radic M., 2012, Neth J Med, 70, 12
- Sivakumar P. V., 2013, Comp Med, 63, 13
- Stewart R. J., 1994, Kidney Int Suppl, 45, S37
- Stills H. F., 1983, Am J Pathol, 113, 222
- Wu H., 2007, Clin Lab, 53, 285
- Yuhas E. M., 1985, Am J Pathol, 119, 83
- Zhang J., 2002, Toxicologist, 66, 15
Cited by
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
Rodríguez-Calero, M. A., Blanco-Mavillard, I., Morales-Asencio, J. M., Fernández-Fernández, I., Castro-Sánchez, E., & de Pedro-Gómez, J. E. (2020) · Heart & Lung · doi:10.1016/j.hrtlng.2020.01.009 · Cited by 78
Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53
“The interpretation of drug-induced vascular lesions in NHPs is made challenging by the occasional observation of spontaneous vascular lesions in cynomolgus macaques (Frazier et al. 2015).”
BackgroundSelf-citationWoicke, J., Al-Haddawi, M., Bienvenu, J.-G., Rae, J. M. C., Chanut, F. J.-A., Colman, K., Cullen, J. M., Davis, W. P., Fukuda, R., Huisinga, M., et al. (2021) · Toxicologic Pathology · doi:10.1177/0192623320968181 · Cited by 49
Colman, K., Andrews, R. N., Atkins, H., Boulineau, T., Bradley, A., Braendli-Baiocco, A., Capobianco, R., Caudell, D. L., Cline, M., Doi, T., et al. (2021) · Journal of Toxicologic Pathology · doi:10.1293/tox.34.1s · Cited by 50
Self-citation
Metadata
- Authors
- Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Ionis Pharmaceuticals (United States) (US)
- WIL Research Europe, Saint-Germain-Nuelles, France
- MedImmune, Cambridge, UK
- Pfizer (United States) (US)
- Raritan, Somerset, New Jersey, USA
- United States Food and Drug Administration (US)
- Genentech (US)
- Corresponding author
- Frazier, Kendall S.
- ORCID
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2015-02-26
- Volume
- 43
- Issue
- 7
- Pages
- 915-934
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2097919342
- Cited by
- 35
- References
- 199
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Toxicologic Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- drug-induced vascular injury, biologic therapy, immunoglobulins, peptides, preclinical toxicology, regulatory toxicology, biomarkers, risk assessment, drug development, feedback regulation
- MeSH terms
- Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Vascular System Injuries, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.